Literature DB >> 30006188

Patient awareness, willingness, and barriers to point-of-care hepatitis C screening in community pharmacy.

Alexander Brewer, Cathy Hanna, Lynne Eckmann, Aric Schadler, Holly Divine.   

Abstract

OBJECTIVES: To determine patients' awareness of the screening recommendations for hepatitis C virus (HCV) in "Baby Boomers," to assess patients' willingness to receive a point-of-care HCV screening test in the pharmacy, and to determine patients' barriers to receiving a point-of-care HCV screening test in a community pharmacy.
METHODS: An anonymous 12-question survey was developed. Five shareholder pharmacies of American Pharmacy Services Corporation (APSC) volunteered to participate. Surveys were mailed to participating pharmacies with instructions to distribute to patients born in 1945 to 1965 at the pharmacy point-of-sale. Data were collected over a 12-week period from October 2016 to January 2017. Completed surveys were collected by participating pharmacies and mailed to the primary investigator. Data were analyzed with the use of descriptive statistics.
RESULTS: Ninety-five eligible surveys were returned and analyzed. A majority of respondents were female (63.00%) and held a bachelor degree or higher (63.16%); 38.95% of patients were aware of HCV age-based risk factors and screening recommendations. Only 9.80% of patients were aware of the fingerstick point-of-care testing (POCT) option for HCV. Nearly three-fourths (71.70%) were willing to receive POCT at a community pharmacy. A majority of patients (65.52%) were unwilling to pay an amount that would cover the cost of testing. Descriptive statistics, including a Pearson chi-square test, were used to analyze the data. Significant differences in the distribution of the percentages of people willing to receive testing and to pay for testing were found among levels of annual household income.
CONCLUSION: A majority of patients are willing to receive POCT at a community pharmacy. Patients were unwilling to pay for testing, however, so pharmacies looking to offer point-of-care HCV screening would need to secure further financial resources, such as insurance reimbursement or grant funding, for this service to be financially feasible.
Copyright © 2018 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30006188     DOI: 10.1016/j.japh.2018.04.031

Source DB:  PubMed          Journal:  J Am Pharm Assoc (2003)        ISSN: 1086-5802


  4 in total

1.  Attitudes toward pharmacy-based HCV/HIV testing among people who use drugs in rural Kentucky.

Authors:  Michelle Duong; Chris Delcher; Patricia R Freeman; April M Young; Hannah L F Cooper
Journal:  J Rural Health       Date:  2021-03-05       Impact factor: 4.333

2.  Point-of-care HIV and hepatitis screening in community pharmacies: a quantitative and qualitative study.

Authors:  Inês Figueira; Inês Teixeira; António Teixeira Rodrigues; Ana Gama; Sónia Dias
Journal:  Int J Clin Pharm       Date:  2022-09-13

3.  Evaluation of the Community Pharmacy Comorbidities Screening Service on Patients with Chronic Diseases.

Authors:  Jędrzej Lewicki; Urszula Religioni; Piotr Merks
Journal:  Patient Prefer Adherence       Date:  2021-07-17       Impact factor: 2.711

4.  Community Pharmacy Engagement in Diabetes Prevention: Key Informant Interviews with Pharmacy Executives.

Authors:  Sara E Roszak; Stefanie P Ferreri
Journal:  Prev Chronic Dis       Date:  2020-08-20       Impact factor: 2.830

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.